Thymidine phosphorylase expression and effect of doxifluridine: a phase II study.
S Sadahiro, Y Otani, K Oya, H Ike, H Shimada, S Yamaguchi, Y Hiki, H Fujita, T Mitomi
Department of Surgery, School of Medicine, Tokai University, Bohseidai, Isehara, Kanagawa 259-1193, Japan. sadahiro@is.icc.u-tokai.ac.jp
Oncology reports 2001 Jul-AugDoxifluridine (5'-DFUR), an active intermediate metabolite of capecitabine, is converted to 5-fluorouracil by thymidine phosphorylase (TP). We used immunohistochemical staining to investigate the relation between TP expression and 5'-DFUR effects in 40 patients with advanced/recurrent lung metastases from colorectal cancer. Cox regression analysis suggested that TP-positive cancer cells (risk ratio 3.72), were independent factors in survival whereas factors in progression-free survival were TP-positive cancer cells (2.93), and TP-positive stromal cells (0.24). It is suggested that TP expression in cancer cells and in stromal cells are opposite prognostic factors in patients treated with 5'-DFUR.
Citation
S Sadahiro, Y Otani, K Oya, H Ike, H Shimada, S Yamaguchi, Y Hiki, H Fujita, T Mitomi. Thymidine phosphorylase expression and effect of doxifluridine: a phase II study. Oncology reports. 2001 Jul-Aug;8(4):753-8
Mesh Tags
Substances
PMID: 11410777
View Full Text
